L. Kareinen

Complete Protection from SARS-CoV-2 Lung Infection in Mice Through Combined Intranasal Delivery of PIKfyve Kinase and TMPRSS2 Protease Inhibitors

This study shows that combining PIKfyve and TMPRSS2 inhibitors intranasally protects mice from SARS-CoV-2 lung infection and reduces cell death.

Inhibition of host N-myristoylation compromises the infectivity of SARS-CoV-2 due to Golgi-bypassing egress from lysosomes and endoplasmic reticulum

This study shows that inhibiting host N-myristoylation reduces SARS-CoV-2 infectivity by impairing viral envelope protein maturation and causing Golgi-bypassing egress.

Nanobody engineering for SARS-CoV-2 neutralization and detection

This study engineers nanobodies to neutralize SARS-CoV-2 variants and develop a detection assay, showing high potency against some variants but limitations against others.

Experimental infection of mink with SARS-COV-2 Omicron (BA.1) variant leads to symptomatic disease with lung pathology and transmission

This study infects mink with SARS-CoV-2 Omicron variant and shows they remain virus positive, develop symptoms, and transmit the virus.

Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariants

This paper describes a novel intranasal inhibitor, TriSb92, that effectively neutralizes SARS-CoV-2 and recent Omicron subvariants, offering protection against infection in mice.